Addex Therapeutics (FRA:APE1) FFO


FRA:APE1 Addex Therapeutics Ltd FRA:APE1
7 GF Score
Price €4.90
GF Value €1.12
! 6 Warning Signs
View Full Analysis

What is Addex Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

FRA:APE1
7GF Score
Addex Therapeutics Ltd FRA:APE1
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Addex Therapeutics (FRA:APE1) Overvalued in 2026?

Based on GuruFocus' analysis, Addex Therapeutics stock appears to be overvalued. The current stock price of €4.90 is trading 337.5% above its estimated GF Value™ of €1.12.

Key valuation signals for FRA:APE1:

  • FFO:
  • GF Value™: €1.12 vs. price of €4.90 (337.5% above fair value)
  • GF Score™: 7/100 with 6 warning signs

No single metric tells the full story. See the FRA:APE1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Addex Therapeutics Business Description

Address Chemin des Mines 9, Geneva, CHE, 1202
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
7GF Score

Get the complete analysis for FRA:APE1

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.90
Price
€1.12
GF Value